Novo Nordisk A/S, the global producer of diabetes products, reported an 8% rise in net sales to DKK 27.2 billion (€3.65 billion) in the first quarter, but its operating profit declined by 11% to DKK 12.3 billion due to a one-time financial gain a year-earlier.
